Why Your Global Patient Journey Map Does Not Work in France
Global patient journey maps miss how the French access system works. Here is where patients actually stall in France, and what launch teams should map instead.
Blog
Insights for pharmaceutical teams entering France.
Thoughtful guidance on launch planning, French market access, stakeholder strategy, and local execution.
What is an Exploitant in France and why you might need one?
The Exploitant: Your key to the French market In France, an ‘Exploitant’ plays a crucial role for any company entering the pharmaceutical market. This legal status allows pharmaceutical companies to import, market, and sell medical products within France. More than just a permit, it acts as your company’s local representative, ensuring all products meet France’s […]
Launching a Pharmaceutical Product in France: A Practical, Step-by-Step Roadmap for International Companies
France remains one of Europe’s most attractive pharmaceutical markets. With a robust reimbursement system, a strong hospital infrastructure, and a population that values medical innovation, France offers significant commercial potential. Yet for many international companies, launching a product in France feels daunting. Multiple stakeholders, a unique “exploitant” requirement, complex pricing negotiations, and an evolving early […]
How Patient Engagement Is Transforming Market Access
In today’s pharmaceutical landscape, success isn’t defined by regulatory approval alone. The real challenge begins after market authorization — when companies must prove value, secure reimbursement, and reach patients faster. One major force reshaping this journey is Patient Engagement. Once considered a “nice-to-have,” it has become a strategic advantage that directly influences Market Access outcomes. […]
How Much Does It Really Cost to Launch a Pharma Product in France?
Expanding into the French market is a major milestone for pharmaceutical and biotech companies. France is not only one of the largest healthcare markets in Europe but also a strategically important entry point for EU commercialization. Yet one of the first questions every executive team asks is:“How much will it cost us to launch in […]
Launch Planning in Pharma: Why Patient and Stakeholder Mapping Matters More Than Ever
Bringing a new therapy to market is one of the most complex and high-stakes undertakings in the pharmaceutical industry. Success is not only about regulatory approval or strong clinical data—it’s also about ensuring the product is launched into an environment that is prepared, receptive, and aligned with patient needs. That’s where patient and stakeholder mapping, […]
Understanding the “NS” Mention in France: What Pharmaceutical Companies Need to Know
Launching and commercializing medicines in France requires navigating a complex regulatory and market access environment. One area that often raises questions among pharmaceutical professionals is the “NS” (Non Substituable) mention, which directly affects prescribing and dispensing practices. What is the NS mention? The NS mention allows prescribers in France to indicate that a prescribed medicine […]
FAQ: The Role of the “Exploitant” in the Pharmaceutical Industry
1. What is an “Exploitant”? In the French pharmaceutical regulatory system, the Exploitant is the legal entity responsible for placing a medicinal product on the French market. It is the entity recorded on the Marketing Authorization (MA) that ensures the product complies with all regulatory, pharmacovigilance, and distribution obligations in France. 2. Is the exploitant […]
Understanding the Reimbursement Process for Prescription Medicines in France
Launching a prescription medicine in France requires more than just obtaining marketing authorization. To ensure patients can access your product — and the French health insurance system (Assurance Maladie) covers its cost — you’ll also need to navigate the reimbursement process. Here’s a step-by-step guide to how it works. 📋 Step 1: Obtain Marketing Authorization […]
How to Choose the Right Exploitant in France: A Practical Guide
When launching a prescription medicine or medical product in France, one of your first and most important decisions is selecting an exploitant. In the unique French regulatory framework, the exploitant is the legal and regulatory entity responsible for placing the product on the market. They hold the marketing authorization, ensure compliance with ANSM requirements, manage […]
How to Bring Your Drug to French Patients Before Approval: Compassionate Use & Accès Précoce Explained
If your company is developing a new medicine and you’re looking at France as part of your European launch, you might wonder:👉 “Is it possible for patients in France to access our drug before we get full marketing authorisation?” The good news: yes, it is possible — thanks to two special early access pathways. These […]
Your 2026 Guide to Pharma Market Access in France
France remains one of the most attractive yet challenging pharmaceutical markets in Europe. With a highly regulated environment, price controls, and a centralised reimbursement system, successfully launching and sustaining your product in France requires a solid understanding of the market access landscape — and how it’s evolving in 2026. Why France? France’s single-payer system ensures […]
White Paper : Navigating the French Pharmaceutical Market
A Comprehensive guide to explore the French MarketUnderstanding the role of Exploitant Introduction The French pharmaceutical market is one of the most complex and highly regulated in Europe, yet it offers substantial opportunities for growth and development. Understanding the local regulatory landscape is essential to ensure successful market entry. A pivotal aspect of this landscape […]
Top 5 mistakes pharma companies make when entering France (and how to avoid them)
Expanding into France can be a lucrative move for pharmaceutical companies, but only if done right. The French healthcare system is unique, highly regulated, and comes with its own set of rules that can catch even seasoned pharma executives off guard. At Elliogen, we specialize in helping pharma companies navigate the complexities of the French […]
Understanding the Pharmaceutical Distribution System in France
France has a highly structured and regulated system for distributing medicines. Whether you're a pharmaceutical company planning to enter the French market or a healthcare professional aiming to navigate the supply chain more efficiently, understanding the different distribution channels and key players is essential. Here’s a clear and up-to-date overview. A Robust and Regulated Infrastructure […]
The Untapped Power of Digital: Revolutionizing Patient Engagement in Pharma
The pharmaceutical landscape is shifting. It's no longer just about developing groundbreaking therapies; it's about ensuring those therapies reach the right patients, at the right time, and that those patients are empowered throughout their journey. Traditional methods of patient recruitment and engagement – relying heavily on clinician referrals and broad-stroke awareness campaigns – are often […]
Parallel Import Opportunities in the EU Pharmaceutical Market: A Complete Guide
In today's increasingly complex pharmaceutical landscape, companies are constantly seeking ways to optimize their market presence and maintain competitive pricing. One often overlooked opportunity in the European Union is parallel importing – a legitimate practice that can offer significant benefits to various stakeholders in the pharmaceutical supply chain. What is Parallel Importing? Parallel importing in […]
Contract Research Organizations (CROs) in France
France is home to one of Europe’s most dynamic pharmaceutical and biotechnology ecosystems, making it a prime location for Contract Research Organizations (CROs). With a robust infrastructure, a commitment to innovation, and a strong regulatory framework, France has emerged as a strategic choice for companies seeking comprehensive research support. Below, we delve into what makes […]
Launching a Pharma Product in Europe: A Country-by-Country Guide for Pharmaceutical Companies
Expanding into Europe is a milestone for many pharmaceutical companies, offering access to one of the world's largest healthcare markets. However, Europe is not a single, homogenous entity—it’s a patchwork of countries, each with unique regulatory requirements, pricing strategies, and market opportunities. A well-planned, localized approach is critical to succeed. Here’s a breakdown of some […]
Mastering Brand Positioning in Prescription-Only Medicine
In the competitive world of prescription-only medicine (POM), brand positioning is crucial. It's not just about having an effective treatment—it's about ensuring your product stands out to healthcare professionals (HCPs), patients, and stakeholders. At Elliogen, we specialize in helping pharmaceutical companies develop tailored brand strategies that resonate and drive success. Why Brand Positioning Matters Trust […]
Unlocking the French Pharmaceutical Market: How U.S. Pharma Companies Can Benefit from a Local Exploitant
Navigating the complexities of the French pharmaceutical market can be daunting for U.S. companies aiming to expand their operations internationally. This is particularly true given the stringent regulatory, safety, and quality standards that France enforces. Understanding the role and advantages of an ‘Exploitant'—a mandatory local representative for pharmaceutical companies—is crucial for any U.S. entity looking […]
Pathways to Approval : Navigating EU Pharmaceutical Regulation through CP and DCP
Introducing a pharmaceutical product into the European Union (EU) necessitates a thorough understanding of the regulatory pathways for obtaining marketing authorization. This is a critical step for pharmaceutical companies aiming to successfully navigate the complex regulatory framework of the EU. There are two principal pathways to consider: the Centralised Procedure (CP) and the Decentralised Procedure […]
Early Access Programs: A Guide for Pharmaceutical Companies
Early Access Programs (EAPs) are a crucial aspect of the pharmaceutical landscape, providing a pathway for patients with serious or life-threatening conditions to access investigational drugs prior to official approval. For pharmaceutical companies, understanding and effectively managing EAPs can be a game-changer. This blog post will delve into what EAPs entail and how pharmaceutical companies […]
Understanding Prescription Dynamics in France: Branded vs. Generic Medication
The French healthcare system offers a unique framework for prescription drugs, impacting pharmaceutical companies, prescribers, and patients alike. As a pharmaceutical company looking to operate in France, it's crucial to understand the dynamics between branded and generic medicines, patient preferences, and the implications of the ‘non substitutable' rule. This understanding is key to developing effective […]
Navigating the French Healthcare Reimbursement System: A guide for Pharmaceutical Companies
The French healthcare system, renowned for its efficiency and universal coverage, presents a unique landscape for pharmaceutical companies looking to expand their market reach. As a pharmaceutical company exploring opportunities in France, it's imperative to understand the intricacies of the French healthcare insurance system. This system's structure and operations significantly impact drug pricing, reimbursement, and […]
Oncology in France: Opportunities for Pharma Companies and CROs
The French oncology sector, renowned for its advanced cancer treatment and research facilities, presents a wealth of opportunities for pharmaceutical companies and Contract Research Organizations (CROs) aiming to enter or expand their presence in the French market. This blog post delves into the main cancer centers in France and the current trends, with a focus […]
Navigating the World of Expanded Access Programs (EAP) in Pharma and Biotech
Why Expanded Access is a Game-Changer in Pharma In the dynamic world of pharma and biotech, the spotlight is increasingly on EAP. These programs are not just about bringing medicines to market; they are about bringing hope to patients facing serious or life-threatening diseases. With information more accessible than ever, patients and advocates worldwide are […]
Understanding Exploitant Status vs Establishing your Regulatory Office
Understanding the French Pharmaceutical Landscape As foreign pharmaceutical companies look to expand their reach into the European market, France stands out as a key player. Known for its robust healthcare system and a population keen on high-quality medical care, France offers a promising avenue for growth. However, navigating the regulatory environment can be challenging. A […]
Understanding "Service Medical Rendu" in the French Healthcare System
The Service Médical Rendu (SMR), or Medical Service Rendered, is a fundamental concept in the French healthcare system, particularly in the context of pharmaceuticals. It is a measure used to evaluate the therapeutic benefit of a medication, which plays a pivotal role in determining its reimbursement by the National Health Insurance (NHI). What is SMR? […]
Navigating the French Healthcare System: Understanding Government Bodies and Their Roles
France's healthcare system is renowned for its efficiency and effectiveness, providing high-quality medical care to its citizens. This success is largely attributed to the various government bodies that oversee different aspects of healthcare. Understanding the roles and connections of these bodies is crucial for anyone looking to engage with the French healthcare sector. Let's take […]
Early Access Program in France
In the heart of France's innovative healthcare landscape, the Early Access Program (EAP), locally known as "Accès Précoce" (formerly "Autorisation Temporaire d’Utilisation" or ATU), stands as a beacon of hope. This remarkable program bridges the gap between urgent patient needs and medical innovation, offering a lifeline to those facing serious or rare diseases with no […]
Centralised Procedure in Europe: A Primer for US-Based Pharmaceutical Companies</strong>
The pharmaceutical industry is a vast landscape of innovation, regulatory standards, and international processes. As US-based pharmaceutical companies expand their operations and look to tap into the European market, it's imperative to understand the regulatory environment. One of the most pivotal regulatory pathways for gaining market access in Europe is the Centralised Procedure. Here's a […]
Infographic – French Pharmaceutical Market
Have a look at our infographic on how the French Pharmaceutical market works, the size and some other valuable information
Navigating the World of Off-Patent Products: Your Guide to Success
Are you considering venturing into the realm of off-patent pharmaceutical products? This market segment offers immense opportunities for growth and diversification of your product portfolio. However, navigating the complexities from initial discussions to the final stages of acquisition and transfer can be daunting. That's where our expertise comes into play. Our Comprehensive Approach At our […]
What affects the supply of medicine in the Pharmaceutical Industry?
What affects the supply of medicine in the Pharmaceutical Industry? One of the main reasons that prescription drug costs make headlines is because of the actors in the supply chain. This study aims to investigate the reasons for the lack of medicines and their effects on the supply of medicines. We could learn more about […]
Enhancing Patient Experience: A Strategic Imperative for Pharmaceutical Companies
In the dynamic world of healthcare, understanding the patient journey—often termed as ‘care flow'—is a crucial aspect that pharmaceutical companies cannot afford to overlook. This journey encompasses a comprehensive visual map of care events, charting the course from the onset of symptoms to the achievement of a cure. Traditionally, the focus within the pharmaceutical industry […]
Exploring the Unique French Retail Pharmacy Market
The retail pharmacy landscape in France presents a fascinating study in uniqueness, distinctly different from its European counterparts. This article delves into the nuances of this market, highlighting what sets French retail pharmacies apart. A Market of Singular Ownership In a striking contrast to many European countries, France does not have pharmacy chains. This means […]
Pharma on social media, good idea?
Due to strict regulations, numerous pharmaceutical companies are very cautious about their presence on the social medias, therefore they often prefer not to play in this game rather than taking any risks. While 50 largest drugmakers worldwide, only half are involved on social media and only 10 of them use all three of the largest […]